GABAB receptors as a therapeutic strategy in substance use disorders: Focus on positive allosteric modulators

@article{Filip2015GABABRA,
  title={GABAB receptors as a therapeutic strategy in substance use disorders: Focus on positive allosteric modulators},
  author={Małgorzata Filip and Małgorzata Frankowska and Anna Sadakierska-Chudy and Agata Suder and Łukasz Szumiec and Pawel Mierzejewski and Przemysław Bienkowski and Edmund Przegaliński and John F. Cryan},
  journal={Neuropharmacology},
  year={2015},
  volume={88},
  pages={36-47}
}
γ-Aminobutyric acid B (GABAB) receptors and their ligands are postulated as potential therapeutic targets for the treatment of several brain disorders, including drug dependence. Over the past fifteen years positive allosteric modulators (PAMs) have emerged that enhance the effects of GABA at GABAB receptors and which may have therapeutic effects similar to those of agonists but with superior side-effect profiles. This review summarizes current preclinical evidence supporting a role of GABAB… Expand
Targeting the GABAB Receptor for the Treatment of Substance Use Disorder
TLDR
This chapter reviews the current preclinical research on the significance of central γ-amino butyric acid (GABA)B receptors in substance use disorder (SUD) and the SUD potential pharmacotherapy based on GABAB receptor ligands, and provides compelling preclinical evidence that GABAB receptors agonists and positive allosteric modulators may have efficacy in the treatment of SUD. Expand
Targeting GABAB receptors for anti-abuse drug discovery
TLDR
The more immediate development of baclofen as a therapeutic for alcohol use disorders may be of significant benefit to some individuals, and genetic and physiological differences are likely to contribute to individual responses to different therapeutic agents. Expand
GABAB Receptors and Drug Addiction: Psychostimulants and Other Drugs of Abuse.
TLDR
Preclinical research suggests that GABABR PAMs are emerging as promising candidates for the treatment of drug addiction, and more are needed, and compounds with better pharmacokinetics and fewer side effects are critically needed. Expand
[GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators].
TLDR
Experimental and clinical data indicating the therapeutic potential of the GABAB receptor agonist, baclofen, in the treatment of alcohol use disorder and substance use disorder are summarized and GABAB PAMs may represent a major step forward in a GABAB receptors-based pharmacotherapy of AUD and SUD. Expand
Efficacy and side effects of baclofen and the novel GABAB receptor positive allosteric modulator CMPPE in animal models for alcohol and cocaine addiction
TLDR
Positive allosteric modulation of the GABAB receptor provides efficacy, and no observable side effects in relapse behavior whereas baclofen may cause, not only sedation, but also considerable impairment of food intake or metabolism, although targeting GABAB receptors may be effective in reducing certain aspects of addictive-like behavior. Expand
KK-92A, a novel GABAB receptor positive allosteric modulator, attenuates nicotine self-administration and cue-induced nicotine seeking in rats
TLDR
Results indicate that KK-92A is a selective GABABR PAM with efficacy in inhibition of the primary reinforcing and incentive motivational effects of nicotine, and attenuation of nicotine seeking, further confirming that GABA BR PAMs may be useful antismoking medications. Expand
Designing modulators of 5-hydroxytryptamine signaling to treat abuse disorders
TLDR
Based on the current evidence, the authors believe that BDNF, as a modulator of the serotonergic pathway, or 5-HT, as one of the modulators of the BDNF system, represent a valuable target to treat drug addiction, which may yield novel therapeutics in the future. Expand
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders
TLDR
Recent progress in research regarding the endocannabinoid systems, cannabis reward versus aversion, and the underlying receptor mechanisms is reviewed, and cannabinoid-based medication development for the treatment of SUDs is reviewed. Expand
Anticonvulsant effects of structurally diverse GABAB positive allosteric modulators in the DBA/2J audiogenic seizure test: Comparison to baclofen and utility as a pharmacodynamic screening model
TLDR
The results presented here suggest the DBA/2J mouse AGS test is a potentially useful screening model for detecting PD effects of GABA(B) PAMs and can provide an initial read-out on target-related motor side-effects. Expand
Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment
TLDR
Light is shed on the role of the GABAergic system and GABA‐B receptors in the shared neurobiology of alcohol‐, feeding‐, and stress‐related behaviors as well as on the pharmacological manipulation of these receptors by orthosteric agonists and positive allosteric modulators. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 164 REFERENCES
GABAB receptors in addiction and its treatment.
TLDR
There is enough evidence to suggest that modulators of the GABA(B) receptor have potential as adjunct treatments to aid in the initiation of abstinence, maintenance of abstinence and prevention of cue-related relapse in some addictions. Expand
Allosteric Modulators of GABAB Receptors: Mechanism of Action and Therapeutic Perspective
TLDR
It is shown that, as expected, these molecules have more pronounced in vivo responses and less side effects than pure agonists, offering new potential therapeutic applications for this new class of GABAB ligands. Expand
Chemistry and pharmacology of GABAB receptor ligands.
  • W. Froestl
  • Chemistry, Medicine
  • Advances in pharmacology
  • 2010
TLDR
This chapter presents new clinical applications of the prototypic GABA(B) receptor agonist bacl ofen for the treatment of addiction by drugs of abuse, a novel baclofen prodrug Arbaclofens placarbil, the GABA( B) receptoragonists AZD3355 (Lesogabaran) currently in Phase 2 clinical trials for the Treatment of gastroesophageal reflux disease, and four positive allosteric modulators of GABA(b) receptors. Expand
The GABAB Receptor-Positive Modulator GS39783 and the GABAB Receptor Agonist Baclofen Attenuate the Reward-Facilitating Effects of Cocaine: Intracranial Self-Stimulation Studies in the Rat
TLDR
Assessment of the ability of the novel GABAB-positive modulator GS39873 or baclofen to modulate the behavioral effects of cocaine strongly suggest that activation of GABAB receptors attenuates the rewarding effects of acute cocaine. Expand
GABAB receptors in reward processes.
TLDR
GA(B) receptor positive modulators are promising therapeutics for the treatment of various aspects of dependence on various drugs of abuse, such as cocaine, nicotine, heroin, and alcohol. Expand
Evaluation of the anxiolytic-like profile of the GABAB receptor positive modulator CGP7930 in rodents
TLDR
The results of this investigation support the premise that GABA(B) receptor positive modulation represents a novel therapeutic strategy for the development of anxiolytic drugs with a superior side-effect profile. Expand
GABA(B) receptors in drug addiction.
TLDR
The present review summarizes the contribution of GABA(B) receptors to the rewarding, locomotor and discriminative stimulus properties of drugs of abuse and their withdrawal symptoms in laboratory animals. Expand
GABAB Receptor-Positive Modulators: Enhancement of GABAB Receptor Agonist Effects In Vivo
TLDR
Examining the in vivo positive modulatory properties of the GABAB receptor-positive modulators provides evidence that CGP7930 and rac-BHFF act in vivo as positive modulators at GABAB receptors mediating loss of righting, but not at neurons mediating hypothermia. Expand
GABAB receptors and depression. Current status.
TLDR
It is argued that the potential antidepressant properties of GABA(B) receptor antagonists may be, at least in part, mediated via these interactions with the serotonergic system and neurotrophic factors, such as BDNF. Expand
Effects of GABAB receptor ligands in animal tests of depression and anxiety.
TLDR
The results indicate that differential manipulation of GABA(B) receptors can modify behaviors relevant to depression and anxiety. Expand
...
1
2
3
4
5
...